Dr. Matasar on the Design of the CHRONOS-3 Trial Examining Copanlisib/Rituximab in Indolent NHL

April 20, 2021
Matthew J. Matasar, MD

Matthew J. Matasar, MD, discusses the design of the phase 3 CHRONOS-3 trial in indolent non-Hodgkin lymphoma.

Matthew J. Matasar, MD, a medical oncologist and Regional Care Network Medical Site Director at Memorial Sloan Kettering Cancer Center Bergen, discusses the design of the phase 3 CHRONOS-3 trial (NCT02367040) in indolent non-Hodgkin lymphoma (iNHL).

In the globally conducted, randomized CHRONOS-3 trial, patients with iNHL received either copanlisib (Aliqopa) plus rituximab (Rituxan) or rituximab plus placebo, Matasar says. Patients were randomized 2:1, meaning that of every 3 patients who enrolled to the trial, 2 patients would receive the combination regimen, while 1 would receive rituximab plus a placebo. A total of 458 patients were randomized; of these patients, 307 received the copanlisib combination and 151 received rituximab plus placebo, Matasar concludes.